Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease
Journal of Clinical Medicine · 27.10.2023 · 12 (21) · 6796
DOI: 10.3390/jcm12216796 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 27.10.2023. Verfasst von Rochelle Wong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, NIH HHS.
Abstract (Originalsprache)
(1) Many patients with inflammatory bowel disease (IBD) in endoscopic remission have persistent histologic activity, which is associated with worse outcomes. There are limited data on the association between adalimumab drug concentrations and histologic outcomes using validated histologic indices. We aimed to assess the relationship between adalimumab concentrations and the Robarts Histopathology Index (RHI). (2) Patients from a tertiary IBD center from 2013 to 2020 with serum adalimumab (ADA) trough concentrations measured during maintenance therapy (≥14 weeks) and a colonoscopy or flexible sigmoidoscopy with biopsies performed within 90 days of drug level were included. Blinded histologic scoring using the RHI was performed. Primary analysis assessed the relationship between adalimumab drug concentrations and histologic remission using receiver operating characteristic curve analysis. (3) In 36 patients (26 Crohn’s Disease, 9 ulcerative colitis, 1 indeterminate), median adalimumab concentrations were higher (17.3 ug/mL, 12.2–24.0) in patients with histologic remission compared to those without (10.3 ug/mL, 6.8–13.9, p = 0.008). The optimal ADA concentration identified using the Youden threshold was ≥16.3 ug/mL (sensitivity 70%, specificity 90%). Patients with ADA ≥ 16.3 ug/mL had higher histologic remission rates (78%) compared to lower ADA concentrations (14%, p= 0.002), as well as higher mucosal healing rates (86%) compared to lower levels (12%, p = 0.001). Symptoms correlated weakly and non-significantly with both histologic (RHI) scores (r = 0.25, p = 0.2) and adalimumab concentrations (r = 0.05, p = 0.8). (4) The current study demonstrated that higher serum adalimumab concentrations (≥16.3 ug/mL) are needed for histologic remission and mucosal healing assessed using the RHI.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
- Department of Pathology, Weill Cornell Medical College, New York, NY 10065, USA.
- Division of Gastroenterology, Centre Hospitalier de l'Universite de Montreal, Montreal, QC H2X 0C1, Canada.
ORCID-Profile: Dana Lukin
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- NIH HHS
- NIH
Zitieren
APA
Wong, R., Qin, L., Pan, Y., Mahtani, P., Longman, R., Lukin, D., Scherl, E., & Battat, R. (2023). Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease. Journal of Clinical Medicine, 12(21), 6796. https://doi.org/10.3390/jcm12216796
Vancouver
Wong R, Qin L, Pan Y, Mahtani P, Longman R, Lukin D, et al. Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease. Journal of Clinical Medicine. 2023;12(21):6796. doi:10.3390/jcm12216796
BibTeX
@article{Wong2023,
author = {Wong, Rochelle and Qin, Lihui and Pan, Yushan and Mahtani, Prerna and Longman, Randy and Lukin, Dana and Scherl, Ellen and Battat, Robert},
title = {Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {21},
pages = {6796},
doi = {10.3390/jcm12216796}
}
EUVIMED